CN102639116A - 四吡咯衍生物的新口服制剂 - Google Patents

四吡咯衍生物的新口服制剂 Download PDF

Info

Publication number
CN102639116A
CN102639116A CN2010800191808A CN201080019180A CN102639116A CN 102639116 A CN102639116 A CN 102639116A CN 2010800191808 A CN2010800191808 A CN 2010800191808A CN 201080019180 A CN201080019180 A CN 201080019180A CN 102639116 A CN102639116 A CN 102639116A
Authority
CN
China
Prior art keywords
photosensitizer
oral
drug
nanoparticles
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800191808A
Other languages
English (en)
Chinese (zh)
Inventor
苏珊娜·格雷斐
尼克雷·尼凡迪夫
弗克尔·阿布莱希特
沃尔夫冈·纽伯格
狄特里希·施格尔曼
维兰德·杰哈德
阿尔诺·维厄
阿尔伯特·法尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Selam Light Technology Co ltd
Biolitec Research GmbH
Original Assignee
Selam Light Technology Co ltd
Biolitec Research GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selam Light Technology Co ltd, Biolitec Research GmbH filed Critical Selam Light Technology Co ltd
Publication of CN102639116A publication Critical patent/CN102639116A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2010800191808A 2009-04-28 2010-04-28 四吡咯衍生物的新口服制剂 Pending CN102639116A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17348709P 2009-04-28 2009-04-28
US61/173,487 2009-04-28
US12/768,244 2010-04-17
US12/768,244 US8815931B2 (en) 2009-04-28 2010-04-27 Oral formulations for tetrapyrrole derivatives
PCT/US2010/032766 WO2010129337A2 (en) 2009-04-28 2010-04-28 New oral formulations for tetrapyrrole derivatives

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201610045032.2A Division CN105641697A (zh) 2009-04-28 2010-04-28 四吡咯衍生物的新口服制剂

Publications (1)

Publication Number Publication Date
CN102639116A true CN102639116A (zh) 2012-08-15

Family

ID=42992670

Family Applications (2)

Application Number Title Priority Date Filing Date
CN2010800191808A Pending CN102639116A (zh) 2009-04-28 2010-04-28 四吡咯衍生物的新口服制剂
CN201610045032.2A Pending CN105641697A (zh) 2009-04-28 2010-04-28 四吡咯衍生物的新口服制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201610045032.2A Pending CN105641697A (zh) 2009-04-28 2010-04-28 四吡咯衍生物的新口服制剂

Country Status (5)

Country Link
US (1) US8815931B2 (https=)
EP (1) EP2429498A4 (https=)
JP (1) JP6142104B2 (https=)
CN (2) CN102639116A (https=)
WO (1) WO2010129337A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9211283B2 (en) * 2009-12-11 2015-12-15 Biolitec Pharma Marketing Ltd Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
EP2875359A4 (en) 2012-03-30 2015-08-19 Charles R Drew University Of Medicine And Science COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING METABOLISM SYNDROME DISEASES
US20140271923A1 (en) 2013-03-14 2014-09-18 Christopher Brian Reid Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions
FI20130341A7 (fi) 2013-11-19 2015-05-20 Oy Safemed Ltd Huonosti vesiliukoisten lääkeaineiden kuljetus metalli-ioneilla tasapainotetun alfafetoproteiinin mukana
EP3201201B1 (en) 2014-09-30 2022-01-26 biolitec unternehmensbeteiligungs II AG Specifically meso-substituted porphyrins and chlorins for photodynamic therapy
CN111701144B (zh) 2015-07-28 2023-03-21 诺欧生物有限责任公司 用于对一氧化氮的光疗调节的系统和方法
US12109429B2 (en) 2015-07-28 2024-10-08 Know Bio, Llc Phototherapeutic light for treatment of pathogens
US10954300B2 (en) 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
ES3011714T3 (en) 2016-02-26 2025-04-08 Biolitec Holding Gmbh & Co Kg Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy
CZ307681B6 (cs) 2016-02-29 2019-02-13 Ústav makromolekulární chemie AV ČR, v. v. i. Fotoaktivovatelná nanočástice pro fotodynamické aplikace, způsob její přípravy, farmaceutická kompozice ji obsahující a jejich použití
EP3225112B2 (de) * 2016-04-01 2025-03-26 TriOptoTec GmbH Photosensibilisator-dispersion und verwendung derselben
WO2020120474A1 (en) 2018-12-10 2020-06-18 Universität Hamburg Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy
WO2020251933A1 (en) 2019-06-10 2020-12-17 The University Of Massachusetts Compositions comprising fullerenyl mesochlorin nano-photosensitizers with covalently bound antibiotics and their uses in combination therapy
US11147984B2 (en) 2020-03-19 2021-10-19 Know Bio, Llc Illumination devices for inducing biological effects
US12447354B2 (en) 2020-03-19 2025-10-21 Know Bio, Llc Illumination devices for inducing biological effects
US12011611B2 (en) 2020-03-19 2024-06-18 Know Bio, Llc Illumination devices for inducing biological effects
US11986666B2 (en) 2020-03-19 2024-05-21 Know Bio, Llc Illumination devices for inducing biological effects
US12347337B2 (en) 2020-12-10 2025-07-01 Know Bio, Llc Enhanced testing and characterization techniques for phototherapeutic light treatments
US12115384B2 (en) 2021-03-15 2024-10-15 Know Bio, Llc Devices and methods for illuminating tissue to induce biological effects
US11654294B2 (en) 2021-03-15 2023-05-23 Know Bio, Llc Intranasal illumination devices

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067508A2 (en) * 2003-01-24 2004-08-12 The Research Foundation Of State University Of Newyork Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles
CN1842322A (zh) * 2003-08-26 2006-10-04 塞拉莫普泰克工业公司 用于光动力疗法的非极性光敏剂制剂
WO2008002460A2 (en) * 2006-06-26 2008-01-03 Bcn Biosciences Llc Orally available light-independent antineoplastic compounds
US20080004847A1 (en) * 2006-06-28 2008-01-03 Schlumberger Technology Corporation Method for updating a model of the earth using microseismic measurements
US20080069781A1 (en) * 2006-09-19 2008-03-20 Ceramoptec Industries Inc. Treatment of periodontal disease with photosensitizers
US20080096857A1 (en) * 2004-02-06 2008-04-24 Qlt Inc. Photodynamic Therapy For The Treatment Of Hyperactive Sebaceous Gland Disorders Using Topically Applied Hydrophobic Green Porphyrins

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
US7264629B2 (en) * 2001-11-09 2007-09-04 Qlt, Inc. Photodynamic therapy for the treatment of hair loss
US7455858B2 (en) * 2002-05-16 2008-11-25 Qlt Inc. Compositions and methods for delivery of photosensitive drugs
WO2007023398A2 (en) * 2005-05-16 2007-03-01 Universite De Geneve Compounds for photochemotherapy
KR100773475B1 (ko) * 2006-07-07 2007-11-05 주식회사 웰스킨 인돌-3-아세트산을 포함하는 광감작제, 및 이를 포함하는광역학적 치료용 키트
GB0712287D0 (en) * 2007-06-22 2007-08-01 Ucl Business Plc Antimicrobial Conjugates
KR100808630B1 (ko) * 2006-12-28 2008-02-29 광주과학기술원 클로린 화합물을 포함하는 경구투여용 항종양 조성물
JP4982208B2 (ja) * 2007-02-27 2012-07-25 テイカ株式会社 光力学的治療法に使用するための光増感剤組成物
US20100183504A1 (en) * 2007-06-14 2010-07-22 Fanqing Frank Chen Multimodal imaging probes for in vivo targeted and non-targeted imaging and therapeutics
WO2009038776A1 (en) * 2007-09-18 2009-03-26 Victor Manneh Therapeutic nanoconjugates

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004067508A2 (en) * 2003-01-24 2004-08-12 The Research Foundation Of State University Of Newyork Use of photodynamic therapy therapeutic agents entrapped in ceramic nanoparticles
CN1842322A (zh) * 2003-08-26 2006-10-04 塞拉莫普泰克工业公司 用于光动力疗法的非极性光敏剂制剂
US20080096857A1 (en) * 2004-02-06 2008-04-24 Qlt Inc. Photodynamic Therapy For The Treatment Of Hyperactive Sebaceous Gland Disorders Using Topically Applied Hydrophobic Green Porphyrins
WO2008002460A2 (en) * 2006-06-26 2008-01-03 Bcn Biosciences Llc Orally available light-independent antineoplastic compounds
US20080004847A1 (en) * 2006-06-28 2008-01-03 Schlumberger Technology Corporation Method for updating a model of the earth using microseismic measurements
US20080069781A1 (en) * 2006-09-19 2008-03-20 Ceramoptec Industries Inc. Treatment of periodontal disease with photosensitizers

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
张丹萍等: "光动力药物的研究与开发", 《药学进展》, vol. 31, no. 12, 31 December 2007 (2007-12-31), pages 529 - 535 *
沈海蓉等: "自微乳释药系统及其制剂的研究进展", 《中国新药与临床杂志》, vol. 24, no. 5, 31 December 2005 (2005-12-31), pages 409 - 412 *

Also Published As

Publication number Publication date
JP6142104B2 (ja) 2017-06-07
US8815931B2 (en) 2014-08-26
EP2429498A4 (en) 2013-02-06
WO2010129337A3 (en) 2011-03-03
EP2429498A2 (en) 2012-03-21
US20100273803A1 (en) 2010-10-28
WO2010129337A2 (en) 2010-11-11
JP2012525409A (ja) 2012-10-22
CN105641697A (zh) 2016-06-08

Similar Documents

Publication Publication Date Title
US8815931B2 (en) Oral formulations for tetrapyrrole derivatives
JP5981139B2 (ja) 親油性または両親媒性治療薬のナノエマルションへの封入
EP0825851B1 (en) Emulsion suitable for administering a poorly water-soluble photosensitizing compound and use thereof
Konan et al. Enhanced photodynamic activity of meso-tetra (4-hydroxyphenyl) porphyrin by incorporation into sub-200 nm nanoparticles
JP3782112B2 (ja) ヒドロ−モノベンゾポルフィリン光増感剤を含有するリポソームの作成方法
KR100923172B1 (ko) 신규 약물 제제
US7354599B2 (en) Liposomal formulations of hydrophobic photosensitizer for photodynamic therapy
EP2509633B1 (en) Nanoparticle carrier system based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy
Zhang et al. Construction and in vitro and in vivo evaluation of folic acid-modified nanostructured lipid carriers loaded with paclitaxel and chlorin e6
WO2004035032A2 (en) Pharmaceutical formulations of camptothecine derivatives
JP2002509877A (ja) 抗癌組成物
JPH11509834A (ja) ヒドロ−モノベンゾポルフィリン光増感剤を含有するリポソームの作成方法
Vargas et al. In vivo photodynamic activity of photosensitizer-loaded nanoparticles: formulation properties, administration parameters and biological issues involved in PDT outcome
BG107862A (bg) Sn-38 липидни комплекси и методи за използването им
CN101653414A (zh) 多西他赛长循环固体脂质纳米粒及其制备方法
Kekani et al. Current advances in nanodrug delivery systems for malaria prevention and treatment
Pegaz et al. Effect of nanoparticle size on the extravasation and the photothrombic activity of meso (p-tetracarboxyphenyl) porphyrin
CN112955152A (zh) 用于预防和/或治疗癌症的黄素腺嘌呤二核苷酸
Esfahani et al. Functionalized and theranostic lipidic and tocosomal drug delivery systems: potentials and limitations in cancer photodynamic therapy
Lim et al. The neovessel occlusion efficacy of 151‐hydroxypurpurin‐7‐lactone dimethyl ester induced with photodynamic therapy
KR101180181B1 (ko) 나노 입자 및 그의 제조 방법
CN110882218B (zh) 脂质体组合物及其制备与应用
CN102772362A (zh) 一种提高生物利用度的氧化石蒜碱组合物及其制剂
Kekani et al. Discover Nano

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20120815